Webinar: Avidity Biosciences - EXPLORE44 Clinical Trial Investigating AOC 1044 (Feb 2023)

Avidity Biosciences joined PPMD for a community webinar on February 8, 2023 to discuss the EXPLORE44™ clinical trial. EXPLORE44 is an ongoing Phase 1/2 clinical trial evaluating AOC 1044 for the treatment of individuals with Duchenne mutations amenable to exon 44 skipping.
AOC 1044 is an antibody oligonucleotide conjugate (AOC™) and is designed to use an antibody to deliver an exon 44-skipping oligonucleotide to muscle and heart cells. AOC 1044 is the first of multiple AOCs Avidity is developing for the Duchenne community.